Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765895 · ClinicalTrials.gov registry record · Phase 3
Nortriptyline for Idiopathic Gastroparesis
A Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
NCT00765895 is a Phase 3 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 130 participants.
The verdict
NCT00765895, a Phase 3 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
Study Summary
The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether treatment with nortriptyline will improve gastroparesis symptoms compared with placebo.
Interventions
- DRUG Nortriptyline Hydrochloride
- DRUG Placebo (for nortriptyline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765895
The ClinicalTrials.gov registry entry for NCT00765895 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nortriptyline Hydrochloride is the first listed.
NCT00765895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765895 about?
NCT00765895 is a clinical study titled "Nortriptyline for Idiopathic Gastroparesis". The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether treatment with nortriptyline will improve gastroparesis symptoms compared with placebo.
What is the current status of trial NCT00765895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2009-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00765895?
The interventions under investigation include: Nortriptyline Hydrochloride (DRUG), Placebo (for nortriptyline) (DRUG).
Who is sponsoring clinical trial NCT00765895?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.